Spots Global Cancer Trial Database for follicular lymphoma
Every month we try and update this database with for follicular lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma | NCT02260804 | Follicular Lymp... | CT-P10 Rituxan | 18 Years - | Celltrion | |
| A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies | NCT00406809 | Chronic Lymphoi... Lymphoid Malign... Non-Hodgkin's L... Follicular Lymp... Mantle Cell Lym... Peripheral T-ce... | ABT-263 | 18 Years - 99 Years | AbbVie | |
| Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi | NCT05929222 | Follicular Lymp... | Radiotherapy Radiotherapy pl... | 18 Years - | Fondazione Italiana Linfomi - ETS | |
| A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers | NCT04328844 | Solid Tumor, Ad... Non-Hodgkin Lym... NSCLC Myelofibrosis Uveal Melanoma | IOA-244 Avelumab Inject... Pemetrexed Cisplatin Ruxolitinib | 18 Years - | iOnctura | |
| GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma | NCT02499003 | Lymphoma, Non-H... | Obinutuzumab an... | 18 Years - | Johannes Gutenberg University Mainz | |
| Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation | NCT03842696 | Hematologic Dis... Acute Leukemia ... Chronic Myeloge... Chronic Myeloge... Chronic Myeloge... Myelodysplastic... Mantle Cell Lym... Follicular Lymp... Diffuse Large B... Non Hodgkin Lym... Graft Vs Host D... Graft-versus-ho... | Vorinostat Blood and Marro... Tacrolimus (or ... Methotrexate Mycophenolate M... Cyclophosphamid... | 3 Years - 39 Years | University of Michigan Rogel Cancer Center | |
| A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma | NCT01569750 | CD20-positive B... | Part 1, Cohort ... Part 1, Cohort ... Part 1, Cohort ... Part 2, Cohort ... Part 2, Cohort ... | 18 Years - | Janssen Research & Development, LLC | |
| Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma | NCT02258529 | Follicular Lymp... Small Lymphocyt... | Idelalisib Rituximab | 18 Years - | Gilead Sciences | |
| Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma | NCT01493479 | Follicular Lymp... | 90Y Ibritumomab... Rituximab | 18 Years - | The Christie NHS Foundation Trust | |
| Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) | NCT02631044 | Non-Hodgkin Lym... Diffuse Large B... Follicular Lymp... Mantle-cell Lym... Primary Mediast... | JCAR017 (lisoca... JCAR017 (lisoca... | 18 Years - | Juno Therapeutics, a Subsidiary of Celgene | |
| Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas | NCT01263418 | Lymphoma, Non-H... Lymphoma, Folli... Lymphoma, B-Cel... Lymphoma, Low-G... Lymphoma, Inter... | Ofatumumab | 70 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity | NCT04503538 | Large B-cell Ly... Diffuse Large B... Primary Mediast... High-grade B-ce... Follicular Lymp... | Telemedicine vi... | 18 Years - | Wake Forest University Health Sciences | |
| A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation | NCT06068881 | Follicular Lymp... Refractory Foll... | Tazverik (Tazem... | 18 Years - | Ipsen | |
| Prospective Observational Study on the Management of Patients With Relapsed or Refractory Follicular Lymphoma (OLYMPE) | NCT02316613 | Follicular Lymp... | Rituximab | 18 Years - | Hoffmann-La Roche | |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | NCT03452774 | Cancer, Metasta... Cancer Cancer of Pancr... Cancer of Liver Cancer of Stoma... Cancer Liver Cancer of Rectu... Cancer of Kidne... Cancer of Esoph... Cancer of Cervi... Cancer of Colon Cancer of Laryn... Cancer, Lung Cancer, Breast Cancer, Advance... Cancer Prostate Cancer of Neck Cancer of Skin Neuroendocrine ... Carcinoma Mismatch Repair... BRCA Gene Rearr... Non Hodgkin Lym... Leukemia Non Small Cell ... Cholangiocarcin... Glioblastoma Central Nervous... Melanoma Urothelial Carc... Bladder Cancer Ovarian Cancer Endometrial Can... Testicular Canc... Breast Cancer COVID Myelofibrosis Myeloproliferat... Myeloproliferat... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Myelodysplastic... | Clinical Trial ... | - | Massive Bio, Inc. | |
| Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies | NCT03151057 | B Cells-Tumors B Cell Chronic ... Follicular Lymp... Mantle Cell Lym... Large B-Cell Di... | Idelalisib 100 ... Placebo Oral Ta... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | NCT02819583 | Acute Lymphocyt... Chronic Lymphoc... Follicular Lymp... Mantle Cell Lym... B-cell Prolymph... Diffuse Large C... | PCAR-019 (anti-... | 18 Years - | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | |
| BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I) | NCT04018248 | Diffuse Large B... Follicular Lymp... Chronic Lymphoc... Small Lymphocyt... B Cell Lymphoma Marginal Zone L... Waldenstrom Mac... Peripheral T Ce... | BR101801 (Phase... BR101801 (Phase... | 18 Years - | Boryung Pharmaceutical Co., Ltd | |
| A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) | NCT02576275 | Indolent Non-Ho... Follicular Lymp... Small Lymphocyt... Marginal Zone L... | Duvelisib Placebo Rituximab Bendamustine | 18 Years - | SecuraBio | |
| TGR1202 in Relapsed and Refractory Follicular Lymphoma | NCT03178201 | Follicular Lymp... | TGR-1202 | 18 Years - | Columbia University | |
| Infusion of Allogeneic, 3rd Party CD19-specific T Cells | NCT02274506 | Blood And Marro... Leukemia Lymphoma | Cyclophosphamid... Fludarabine T-Cell Infusion | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases | NCT00376519 | Graft Versus Ho... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... Secondary Myelo... | cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... Treg cell infus... umbilical cord ... total-body irra... | 18 Years - 45 Years | Masonic Cancer Center, University of Minnesota | |
| TGR1202 in Relapsed and Refractory Follicular Lymphoma | NCT03178201 | Follicular Lymp... | TGR-1202 | 18 Years - | Columbia University | |
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | NCT06022029 | Triple Negative... Diffuse Large B... Follicular Lymp... Lymphoma, Non-H... Mantle Cell Lym... Bladder Cancer Uveal Melanoma,... Cervix Cancer Carcinoma in Si... Head and Neck S... Skin Cancer Metastatic Canc... Tumor, Solid Tumor Recurrenc... | ONM-501 Cemiplimab | 18 Years - | OncoNano Medicine, Inc. | |
| Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma | NCT01306643 | Indolent Non-Ho... Follicular Lymp... Small Lymphocyt... Marginal Zone L... | Idelalisib | 18 Years - | Gilead Sciences | |
| Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma | NCT01118845 | Non-Hodgkin's L... Lymphoma, Large... Diffuse, Mantle... Follicular Lymp... Large B-Cell, D... | SyB L-0501 Rituximab | 20 Years - 75 Years | SymBio Pharmaceuticals | |
| Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma | NCT01121757 | Follicular Lymp... Marginal Zone L... | azacitidine lenalidomide | 18 Years - | Duke University | |
| Treatment of Follicular Lymphoma With High Dose Therapy and Stem Cell Support Followed by Rituximab and Alpha Interferon | NCT03069248 | Follicular Lymp... | Rituximab Alpha Interfero... | 18 Years - 65 Years | Sunnybrook Health Sciences Centre | |
| Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel | NCT05776160 | Large B-cell Ly... Follicular Lymp... | Axicabtagene Ci... | 18 Years - | Gilead Sciences | |
| Multicentric Study, Three Randomized Arms (R-CVP vs R-CHOP vs R-FM),for Patients With Stage II-IV Follicular Lymphoma | NCT00774826 | Follicular Lymp... | R-CVP R-CHOP R-FM | 18 Years - 75 Years | Fondazione Italiana Linfomi - ETS | |
| Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma | NCT04849351 | Marginal Zone L... Follicular Lymp... | HMPL-689 | 18 Years - | Hutchmed | |
| Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas | NCT01732926 | Indolent Non-Ho... | Idelalisib Rituximab Bendamustine Placebo | 18 Years - | Gilead Sciences | |
| Rituximab Maintenance Treatment of Newly Diagnosed Follicular Lymphoma After BR or RCHOP or R2: a Multicenter Clinical Study | NCT04842318 | Follicular Lymp... | BR for 6 cycles... RCHOP for 6 cyc... R2 for 6 cycles... | 18 Years - | Ruijin Hospital | |
| Immunochemotherapy, Zevalin, and Bone Marrow Transplant for Follicular Lymphoma | NCT01130194 | Follicular Lymp... | Combination of ... | 18 Years - 80 Years | St. Louis University | |
| A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma | NCT01974440 | Lymphoma | Bendamustine Rituximab Cyclophosphamid... Doxorubicin Vincristine Prednisone PCI-32765 (Ibru... Placebo | 18 Years - | Janssen Research & Development, LLC | |
| A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma | NCT01317901 | B-cell Small Ly... | TRU-016 Bendamustine Rituximab | 18 Years - 99 Years | Aptevo Therapeutics | |
| Lenalidomide and R-CHOP in B-cell Lymphoma | NCT00901615 | Lymphoma, Large... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... | Lenalidomide an... | 18 Years - 70 Years | Lymphoma Study Association | |
| A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers | NCT04328844 | Solid Tumor, Ad... Non-Hodgkin Lym... NSCLC Myelofibrosis Uveal Melanoma | IOA-244 Avelumab Inject... Pemetrexed Cisplatin Ruxolitinib | 18 Years - | iOnctura | |
| Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma | NCT00904722 | Lymphoma | CT-011 Rituximab | 18 Years - | M.D. Anderson Cancer Center | |
| Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML | NCT02238522 | Lymphoprolifera... Acute Myeloid L... | ZEN003365 | 18 Years - | Zenith Epigenetics | |
| Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas | NCT04305444 | Relapsed Chroni... Refractory Chro... Diffuse Large B... Follicular Lymp... Richter's Trans... | DTRM-555 | 18 Years - | Zhejiang DTRM Biopharma | |
| Phase II Cancer Vaccine Trial for Patients With Follicular Lymphoma | NCT01926639 | Follicular Lymp... | Radiotherapy, r... | 18 Years - | Oslo University Hospital | |
| Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML | NCT02238522 | Lymphoprolifera... Acute Myeloid L... | ZEN003365 | 18 Years - | Zenith Epigenetics | |
| Untreated FolliculaR Lymphoma Treated With OBinituzumAb in a Non-interventional Study (URBAN) | NCT04034056 | Follicular Lymp... | Obinutuzumab | 18 Years - | Hoffmann-La Roche | |
| Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype | NCT00001572 | B Cell Lymphoma Follicular Lymp... Neoplasm | Id-KLH Vaccine QS-21 (Stimulat... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) | NCT01691898 | Follicular Lymp... Diffuse Large B... | Obinutuzumab Pinatuzumab Ved... Polatuzumab Ved... Rituximab | 18 Years - | Genentech, Inc. | |
| A Phase II Trial of Intermediate Radiation Dose For Lymphoma | NCT05284825 | Follicular Lymp... | 12 Gy in 6 dail... | 18 Years - | Sunnybrook Health Sciences Centre | |
| Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituximab in Patients With Follicular Lymphoma | NCT02423837 | Follicular Lymp... | Rituximab, bend... | 18 Years - 75 Years | National Research Center for Hematology, Russia | |
| Hypnosis: a Path to Appeasement | NCT05942885 | Hematologic Can... | anxiety questio... | 18 Years - | Hospices Civils de Lyon | |
| Infusion of Allogeneic, 3rd Party CD19-specific T Cells | NCT02274506 | Blood And Marro... Leukemia Lymphoma | Cyclophosphamid... Fludarabine T-Cell Infusion | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Efficacy of Palliative Low-Dose Involved-Field Radiation Therapy for Recurrent Advanced Follicular Lymphoma | NCT02438501 | Recurrent Folli... | Low-dose involv... Involved-field ... | 18 Years - 65 Years | Wuhan University | |
| Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients | NCT02877082 | Acute Leukemia Chronic Lymphoc... Chronic Myeloge... Diffuse Large B... Follicular Lymp... Graft Versus Ho... Mantle Cell Lym... Marginal Zone L... Myelodysplastic... Myelofibrosis Myeloproliferat... Small Lymphocyt... | Thymoglobulin Bortezomib Tacrolimus | 18 Years - 75 Years | Emory University | |
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | NCT06022029 | Triple Negative... Diffuse Large B... Follicular Lymp... Lymphoma, Non-H... Mantle Cell Lym... Bladder Cancer Uveal Melanoma,... Cervix Cancer Carcinoma in Si... Head and Neck S... Skin Cancer Metastatic Canc... Tumor, Solid Tumor Recurrenc... | ONM-501 Cemiplimab | 18 Years - | OncoNano Medicine, Inc. | |
| Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma | NCT01476787 | Follicular Lymp... | Rituximab Lenalidomide Rituximab-CHOP Rituximab-CVP Rituximab-Benda... | 18 Years - | Celgene | |
| Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas | NCT01732913 | Indolent Non-Ho... | Placebo Rituximab Idelalisib | 18 Years - | Gilead Sciences | |
| Efficacy of COVID-19 Vaccination in Patientstreated With Anti-CD20 for Follicular Lymphoma or Mantle Cell Lymphoma | NCT04918940 | Follicular Lymp... Mantle Cell Lym... | Determination o... | 18 Years - | Centre Henri Becquerel | |
| Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma | NCT01078142 | Follicular Lymp... Mantle Cell Lym... | Temsirolimus, R... | 18 Years - | Johannes Gutenberg University Mainz | |
| Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL | NCT03019666 | Multiple Myelom... Non-Hodgkin Lym... Diffuse Large B... Mantle-Cell Lym... Follicular Lymp... Indolent B Cell... Primary Mediast... Lymphoplasmacyt... | Nicotinamide Ex... | 18 Years - 70 Years | Masonic Cancer Center, University of Minnesota | |
| BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL) | NCT03520920 | Marginal Zone L... Follicular Lymp... Diffuse Large B... | Zanubrutinib Rituximab | 18 Years - | BeiGene | |
| Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies | NCT01947140 | Lymphoid Malign... Multiple Myelom... Lymphoma Hodgkin Lymphom... Non-hodgkin Lym... | Pralatrexate Romidepsin | 18 Years - | Columbia University | |
| Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma | NCT03976102 | Follicular Lymp... | DRL_RI (Propose... MabThera® | 18 Years - | Dr. Reddy's Laboratories Limited | |
| A Study of AZD0486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | NCT04594642 | B-cell Non Hodg... Diffuse Large B... High-grade B-ce... Follicular Lymp... | AZD0486 IV | 18 Years - 130 Years | AstraZeneca | |
| Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL | NCT03019666 | Multiple Myelom... Non-Hodgkin Lym... Diffuse Large B... Mantle-Cell Lym... Follicular Lymp... Indolent B Cell... Primary Mediast... Lymphoplasmacyt... | Nicotinamide Ex... | 18 Years - 70 Years | Masonic Cancer Center, University of Minnesota | |
| A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma | NCT01974440 | Lymphoma | Bendamustine Rituximab Cyclophosphamid... Doxorubicin Vincristine Prednisone PCI-32765 (Ibru... Placebo | 18 Years - | Janssen Research & Development, LLC | |
| Trial of Low-Dose Methotrexate and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma | NCT01389076 | Follicular Lymp... | Bexxar Low Dose Methot... | 18 Years - | University of Michigan Rogel Cancer Center | |
| A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma | NCT00315731 | Lymphoma, Folli... | Follicular Lymp... | 18 Years - | GlaxoSmithKline | |
| Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma | NCT05783596 | Follicular Lymp... Marginal Zone L... Indolent Non-ho... | Obinutuzumab Glofitamab | 18 Years - | Dana-Farber Cancer Institute | |
| Antiviral Agent HARVONI® for the Treatment of HCV-associated Indolent B-Cell Lymphoma | NCT03261349 | Indolent Lympho... | Ledipasvir and ... | 20 Years - | National Taiwan University Hospital | |
| FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma | NCT05934097 | Diffuse Large B... Transformed Ind... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... | FT596 Cyclophosphamid... Doxorubicin Vincristine Prednisone Rituximab Bendamustine | 18 Years - | Fate Therapeutics | |
| A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | NCT03740529 | Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Marginal Zone L... B-cell Lymphoma Small Lymphocyt... | Pirtobrutinib Venetoclax Rituximab | 18 Years - | Eli Lilly and Company | |
| Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers | NCT05749549 | Advanced Cancer Follicular Lymp... Peripheral T Ce... Diffuse Large B... | BR1733 | 18 Years - | Shanghai Blueray Biopharma Co., Ltd. | |
| Autologous Transplant in HIV Patients (BMT CTN 0803) | NCT01141712 | Lymphoma HIV | Autologous tran... BCNU Etoposide Cytarabine Melphalan | 15 Years - | Medical College of Wisconsin | |
| Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Follicular Lymphoma | NCT02449252 | Follicular Lymp... | Consolidation i... Consolidation i... cyclophosphamid... doxorubicin vincristine prednisone | 18 Years - 65 Years | Wuhan University | |
| Consolidation Treatment With Y90-Ibritumomab Tiuxetan After R-CHOP Induction in High Risk Patients According to Follicular Lymphoma International Prognostic Index (FLIPI) With Follicular Lymphoma | NCT00722930 | Follicular Lymp... | Y90 Ibritumomab... | 18 Years - | Grupo Oncológico para el Tratamiento y el Estudio de los Linfomas | |
| Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | NCT03314974 | Acute Leukemia Acute Myeloid L... Acute Lymphobla... Lymphoma Chronic Myeloge... Plasma Cell Leu... Myeloproliferat... Myelofibrosis Myelodysplasia Refractory Anem... High Risk Anemi... Chronic Lymphoc... Small Lymphocyt... Marginal Zone B... Follicular Lymp... Lymphoplasmacyt... Mantle-Cell Lym... Prolymphocytic ... Diffuse Large C... Lymphoblastic L... Burkitt Lymphom... High Grade Non-... Multiple Myelom... Juvenile Myelom... Biphenotypic/Un... MRD Positive Le... Natural Killer ... Acquired Bone M... | HSCT with TBI R... HSCT with Non-T... | - 60 Years | Masonic Cancer Center, University of Minnesota | |
| A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas | NCT02401048 | Diffuse Large B... Follicular Lymp... | Ibrutinib MEDI4736 | 18 Years - | Pharmacyclics LLC. | |
| Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL | NCT06151080 | DLBCL - Diffuse... Follicular Lymp... | Lenalidomide co... | 18 Years - 70 Years | The First Affiliated Hospital of Xiamen University | |
| Randomized Study for Patients With Follicular Lymphoma Needing Treatment | NCT00140569 | Follicular Lymp... | CHVP + interfer... fludarabine CHOP + TBI and ... | 18 Years - | Lymphoma Study Association | |
| Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas | NCT01282424 | Follicular Lymp... Small Lymphocyt... Lymphoplasmacyt... Marginal Zone L... | Idelalisib | 18 Years - | Gilead Sciences | |
| A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma | NCT04722601 | Follicular Lymp... | Venetoclax Obinutuzumab CC-486 | 18 Years - | University of Chicago |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
